Our Ubika Marijuana Stock Index soared 161% since our last report dated October 30, 2017
This Content is Exclusive to Our Members
The Ubika Marijuana 20 Index has risen sharply since our last report dated October 30, 2017, returning 161%, outperforming the TSXV Index and the Horizons Marijuana Life Sciences Index over the same period, which returned 16%, and 137%, respectively. Every component of our index has gained after a sudden spike in marijuana stocks post Christmas. Notable performers in this report include:
MedReleaf Corp. (TSX:LEAF), which jumped 86% after the Company announced a deal to supply medical cannabis to Shoppers Drug Mart.
Emerald Health Therapeutics Inc. (TSXV:EMH), which rose 27% after the Company announced a $15 Million prospectus sale.
Aurora Cannabis Inc. (TSX:ACB), which increased 18% as California opened their state markets, and jumped another 27% after the Company announced it sold $3.1 Million in marijuana.
Disclosure: Neither the author nor his/her family own shares in any of the companies mentioned above.
To read our full disclosure, please click on the button below:
The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source. Ubika and/or its affiliates and/or their respective officers, directors or employees may from time to time acquire, hold or sell securities and/or commodities and/or commodity futures contracts in certain underlying companies mentioned in this site and which may also be clients of Ubika’s affiliates. In such instances, Ubika and/or its affiliates and/or their respective officers, directors or employees will use all reasonable efforts to avoid engaging in activities that would lead to conflicts of interest and Ubika and/or its affiliates will use all reasonable efforts to comply with conflicts of interest disclosures and regulations to minimize the conflict.